MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

78.45
-2.16
-2.68%
After Hours: 78.45 0 0.00% 16:55 02/25 EST
OPEN
79.85
PREV CLOSE
80.61
HIGH
80.64
LOW
77.74
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
110.37
52 WEEK LOW
62.48
MARKET CAP
17.25B
P/E (TTM)
-56.2648
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Incyte Corp. stock falls Thursday, underperforms market
marketwatch.com · 10h ago
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
GlobeNewswire · 10h ago
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
Zacks.com · 20h ago
Incyte Corp. stock rises Wednesday, outperforms market
Shares of Incyte Corp. rallied 2.01% to $80.61 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
marketwatch.com · 1d ago
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
Zacks.com · 1d ago
Nasdaq 100 Movers: VRSK, INCY
Feb 24, 2021 (MarketNewsVideo.com via COMTEX) -- In early trading on Wednesday, shares of Incyte topped the list of the day's best performing components of...
MarketNewsVideo.com · 1d ago
Tyrosine Kinase JAK Inhibitors Market Study Applications, Types and Market Analysis including Growth, Trends and Forecasts 2020 to 2027 By Ameco Research
pune, India, Wed, 24 Feb 2021 00:34:52 / Comserve Inc. / -- The global Tyrosine Kinase JAK Inhibitors market size is projected to reach US$ 320630 million by...
Comserve · 2d ago
Incyte Corp. stock underperforms Tuesday when compared to competitors
Shares of Incyte Corp. slipped 1.13% to $79.02 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
marketwatch.com · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INCY. Analyze the recent business situations of Incyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INCY stock price target is 105.38 with a high estimate of 136.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 835
Institutional Holdings: 218.17M
% Owned: 99.24%
Shares Outstanding: 219.84M
TypeInstitutionsShares
Increased
179
8.64M
New
112
796.39K
Decreased
166
8.19M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/President/Chief Executive Officer/Director
Herve Hoppenot
Chief Financial Officer/Executive Vice President
Christiana Stamoulis
Executive Vice President/Chief Scientific Officer
Dashyant Dhanak
Executive Vice President/General Counsel
Maria Pasquale
Executive Vice President/Director of Human Resources
Paula Swain
Executive Vice President
Barry Flannelly
Executive Vice President
Vijay Iyengar
Executive Vice President
Steven Stein
Executive Vice President
Wenqing Yao
Lead Director/Independent Director
Julian Baker
Independent Director
Jean-Jacques Bienaime
Independent Director
Paul Clancy
Independent Director
Wendy Dixon
Independent Director
Jacqualyn Fouse
Independent Director
Paul Friedman
Independent Director
Edmund Harrigan
Independent Director
Katherine High
  • Dividends
  • Splits
  • Insider Activity
No Data
About INCY
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.